FDA 483 - Baxter Oncology GmbH - September 18, 2025

This FDA 483 document outlines significant Current Good Manufacturing Practice (cGMP) violations observed at Baxter Oncology GmbH"s Halle (Westf.), Germany facility during an inspection from September 18-26, 2025. The observations primarily concern the manufacture of sterile drug products, highlighting critical deficiencies across multiple areas.Key issues include inadequate validation of aseptic and sterilization processes, such as insufficient investigations into failed revalidations and unrepresentative media fills. Contamination control procedures were found deficient, with aseptic technique breaches, the use of filters failing integrity tests, and the presence of fibers from manufacturing materials. The facility"s cleaning and disinfection systems were ineffective, leading to residual moisture and microbiological contamination in critical Grade A areas. Equipment design for purified water systems also contributed to microbial excursions.Furthermore, the Quality Control Unit demonstrated a lack of thorough investigation into foreign particulate matter in products and out-of-specification assay results, often attributing issues to generic causes without sufficient scientific justification. Significant data integrity and document control failures were noted, with original GMP records found discarded or batch records improperly altered by production personnel without Quality Unit approval. Environmental monitoring practices were also insufficient in critical aseptic zones, and pest infestation was identified in a controlled area.Baxter Oncology GmbH is required to thoroughly investigate these observations, implement comprehensive corrective and preventive actions, and demonstrate sustainable compliance with cGMP regulations to ensure the quality, purity, and safety of its drug products.